HILSX
Price
$28.41
Change
+$0.29 (+1.03%)
Updated
Aug 21 closing price
Net Assets
16.52B
TROZX
Price
$27.89
Change
+$0.31 (+1.12%)
Updated
Aug 21 closing price
Net Assets
17.34B
Interact to see
Advertisement

HILSX vs TROZX

HILSX vs TROZX Comparison Chart in %
View a ticker or compare two or three
VS
HILSX vs. TROZX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HILSX is a StrongBuy and TROZX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TROZX (17.3B) and HILSX (16.5B) have equal amount of cash in the bank . TROZX pays higher dividends than HILSX: TROZX (2.83) vs HILSX (2.44). HILSX was incepted earlier than TROZX: HILSX (16 years) vs TROZX (6 years). HILSX (1.19) is less costly to investors than TROZX (0.65). HILSX is a more actively managed with annual turnover of: 19.00 vs. TROZX (15.00). HILSX (0) and TROZX (0) have matching initial minimum investment requirements. TROZX annual gain was more profitable for investors over the last year : 28.78 vs. HILSX (24.48). TROZX (110.86) and HILSX (106.66) have equivalent 5 years return.
HILSXTROZXHILSX / TROZX
Total Expense Ratio1.190.00-
Annual Report Gross Expense Ratio1.190.65183%
Fund Existence16 years6 years-
Gain YTD18.62218.078103%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets16.5B17.3B95%
Annual Yield % from dividends2.442.8386%
Returns for 1 year24.4828.7885%
Returns for 3 years85.62101.4084%
Returns for 5 years106.66110.8696%
Returns for 10 years142.22N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGKIX12.610.25
+2.02%
Morgan Stanley Global Permanence I
BIVRX18.630.13
+0.70%
Invenomic Investor
ESPRX42.380.23
+0.55%
Allspring Special Small Cap Value R6
FFCMX23.27N/A
N/A
Fidelity Advisor Asset Manager 50% C
IJSTX13.94N/A
N/A
VY® JPMorgan Small Cap Core Equity S2